News
KNSA
20.59
+0.49%
0.10
Weekly Report: what happened at KNSA last week (1216-1220)?
Weekly Report · 8h ago
Weekly Report: what happened at KNSA last week (1209-1213)?
Weekly Report · 12/16 09:12
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 12/12 04:38
Weekly Report: what happened at KNSA last week (1202-1206)?
Weekly Report · 12/09 09:11
Insider Sale: CHIEF FINANCIAL OFFICER of $KNSA (KNSA) Sells 1,123 Shares
Barchart · 12/06 04:34
Insider Sale: CHIEF ACCOUNTING OFFICER of $KNSA (KNSA) Sells 9 Shares
Barchart · 12/03 01:52
Weekly Report: what happened at KNSA last week (1125-1129)?
Weekly Report · 12/02 09:11
Weekly Report: what happened at KNSA last week (1111-1115)?
Weekly Report · 11/18 09:10
Weekly Report: what happened at KNSA last week (1104-1108)?
Weekly Report · 11/11 09:11
Kiniksa Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by JP Morgan
Dow Jones · 11/05 16:10
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 11/05 16:10
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $40
Benzinga · 11/05 16:00
J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
TipRanks · 11/05 12:19
Weekly Report: what happened at KNSA last week (1028-1101)?
Weekly Report · 11/04 09:11
Kiniksa Pharmaceuticals (KNSA) Stock Drops 17%, Presenting a Potential Opportunity
TipRanks · 10/31 13:09
Kiniksa Pharmaceuticals Faces Financial Risks from Global Currency Fluctuations
TipRanks · 10/31 06:00
Kiniksa Pharmaceuticals Price Target Raised to $35.00/Share From $30.00 by Evercore ISI Group
Dow Jones · 10/30 15:07
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 10/30 15:07
Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $35
Benzinga · 10/30 14:57
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations
Simply Wall St · 10/30 12:38
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals International, plc through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.